Fennec Pharma COO Adrian Haigh Departs, Effective June 30, 2024

7/1/24 6:08:05 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $FENC alert in real time by email

Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer.

Get the next $FENC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FENC

Date	Price Target	Rating	Analyst
11/22/2022	$9.00 → $12.00	Neutral → Overweight	Cantor Fitzgerald
9/7/2022	$11.00	Overweight	CapitalOne
8/8/2022	$14.00	Buy	Craig Hallum

More analyst ratings

$FENC
Financials

Live finance-specific insights

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ
11/7/24 6:13:00 AM ET
$FENC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Thursday, November 7, 2024Time:8:30 a.m. Eastern TimeLink:https://edge.media-server.com/mmc/p/e6my278s To access the conference call, please register using https://edge.media-server.com/mmc/p/e6m
10/31/24 6:23:00 AM ET
$FENC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2024, and provided a business update. "We continued to execute well in the second quarter and are encouraged by the early third quarter m
8/13/24 6:05:00 AM ET
$FENC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event. Conference Details: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton New York Times Square Hotel, New York City About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce t
11/13/24 6:27:00 AM ET
$FENC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ
11/7/24 6:13:00 AM ET
$FENC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Thursday, November 7, 2024Time:8:30 a.m. Eastern TimeLink:https://edge.media-server.com/mmc/p/e6my278s To access the conference call, please register using https://edge.media-server.com/mmc/p/e6m
10/31/24 6:23:00 AM ET
$FENC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Fennec Pharma COO Adrian Haigh Departs, Effective June 30, 2024

Chat with this insight

Recent Analyst Ratings for $FENC

$FENC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF FINANCIAL OFFICER Andrade Robert exercised 15,816 shares at a strike of $2.45, increasing direct ownership by 14% to 127,381 units (SEC Form 4)

SEC Form 4 filed by Chief Strategy Officer Cioffi Christiana Marie

SEC Form 4 filed by Chief Commercial Officer Evans Terry L

$FENC Leadership Updates

Live Leadership Updates

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

$FENC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Fennec Pharmaceuticals upgraded by Cantor Fitzgerald with a new price target

CapitalOne initiated coverage on Fennec Pharmaceuticals with a new price target

Craig Hallum resumed coverage on Fennec Pharmaceuticals with a new price target

$FENC FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for PEDMARK issued to FENNEC PHARMACEUTICALS INC

$FENC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Fennec Pharmaceuticals Inc.

SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

$FENC Financials

Live finance-specific insights

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

$FENC SEC Filings

SEC Form 10-Q filed by Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Fennec Pharmaceuticals Inc.

$FENC Press Releases

Fastest customizable press release news feed in the world

$FENC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$FENC Market Insights

Live Market Insights

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Andrade Robert bought 12,500 shares, increasing direct ownership by 14% to 104,271 units (SEC Form 4)

Raykov Rosty bought 29,167 shares, increasing direct ownership by 10% to 316,638 units (SEC Form 4)

Fennec Pharma COO Adrian Haigh Departs, Effective June 30, 2024

Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Lowers Price Target to $17

HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Lowers Price Target to $15

Recent Analyst Ratings for
$FENC

$FENC
Insider Trading

$FENC
Leadership Updates

$FENC
Analyst Ratings

$FENC
FDA approvals

$FENC
Large Ownership Changes

$FENC
Financials

$FENC
SEC Filings

$FENC
Press Releases

$FENC
Insider Purchases

$FENC
Market Insights